Chemed Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHE research report →
Range $620 – $650
Price Chart
About the company
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
- CEO
- Kevin J. McNamara
- IPO
- 1973
- Employees
- 15,811
- HQ
- Cincinnati, OH, US
Get TickerSpark's AI analysis on CHE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.14B
- P/E
- 26.10
- Fwd P/E
- 21.28
- PEG
- 2.62
- P/S
- 2.67
- P/B
- 8.29
- EV/EBITDA
- 16.72
- Div Yield
- 0.48%
- Gross Margin
- 31.65%
- Op Margin
- 13.94%
- Net Margin
- 10.61%
- ROE
- 32.10%
- ROIC
- 19.17%
Latest fiscal year · YoY change
- Revenue
- $2.53B+4.1%
- Gross Profit
- $758.34M-11.2%
- Op Income
- $338.25M
- Net Income
- $265.24M-12.2%
- EPS
- $18.42-8.4%
- OCF Growth
- -7.0%
- FCF Growth
- -11.5%
- 52W High
- $562.24
- 52W Low
- $365.21
- 50D MA
- $519.53
- 200D MA
- $469.86
- Beta
- 0.49
- RSI (14)
- 59
- Avg Volume
- 154.31K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Chemed delivered strong third-quarter growth led by VITAS, while Roto-Rooter grew revenue but saw margin pressure from marketing and fuel costs.· October 28, 2026
- VITAS revenue rose 12.2% year over year and adjusted net income increased 44.7%, with strong admissions growth and lower Medicare cap pressure.
- Roto-Rooter revenue increased 7.5% and same-store revenue rose 5.5%, but adjusted EBITDA declined 2.5% as marketing and fuel costs rose.
- Chemed said it ended the Medicare cap year with more than $34 million of cushion in Florida and did not expect a Florida cap billing limitation in 2027.
- Management remained upbeat on VITAS staffing and on Roto-Rooter’s long-term margin recovery, despite near-term pressure from paid search and acquisition integration.
- The company repurchased 125 thousand shares for $66 million and still had $73.7 million of share repurchase authorization remaining at quarter-end.
Chemed said total company revenue increased 10.6% year over year and adjusted diluted EPS increased 28.1% in the third quarter. VITAS net revenue was $457.4 million, up 12.2% versus last year; adjusted EBITDA excluding Medicare cap was $92.5 million, up 31.4%, with an adjusted EBITDA margin of 20.2%. Roto-Rooter branch commercial revenue was $59.9 million, up 9%, branch residential revenue was $158.8 million, up 5.2%, and adjusted EBITDA was $48.2 million, down 2.5%, with a 20.6% margin. The company said it expects to finish 2026 at or slightly above the high end of its full-year adjusted EPS guidance from the second quarter.
Kevin McNamara emphasized that VITAS continues to perform at a very high level, with ADC growth and cost containment driving strong profit growth. He also highlighted Roto-Rooter’s revenue momentum, saying same-store growth exceeded internal expectations and that the company expects the business to return to its historical margin pattern over time as revenue growth stabilizes. His tone was confident but cautious, especially around Roto-Rooter marketing costs and the need to avoid overpromising on guidance.
Michael Witzeman focused on the hard numbers behind the quarter: VITAS revenue of $457.4 million, days of care up 9.4%, average revenue per patient day of $209.11, and adjusted EBITDA excluding Medicare cap of $92.5 million at a 20.2% margin. On Roto-Rooter, he cited $59.9 million of commercial revenue, $158.8 million of residential revenue, and a $48.2 million adjusted EBITDA result, noting the margin was pressured by customer acquisition costs and about $1.4 million of higher fuel costs. He also quantified capital allocation, saying the company repurchased 125 thousand shares for $66 million and had $73.7 million of remaining authorization, while noting more than $229 million of operating cash flow over the first nine months of 2026.
Analysts pressed management on staffing, wage inflation, Medicare cap allowances, Roto-Rooter lead generation, and the impact of acquisitions on margins. Management said VITAS is not having difficulty hiring or retaining nurses and does not expect a material increase in recruiting costs in 2027; it also said the higher contractual allowance reflects more audit activity and should not be viewed as a major concern. On Roto-Rooter, management said Google-related paid lead costs remain a headwind, but free and app-generated leads are still growing and the company sees a natural floor supported by repeat customers and the brand. They also explained that acquired franchise territories have much lower initial EBITDA margins, so revenue comes in quickly while margin improvement takes 12 to 18 months.
The bull case from this call is that VITAS is still delivering strong growth with improving profitability, while management sees no hiring bottleneck and expects the patient mix to remain manageable. Roto-Rooter is also growing faster than historical industry trends, and management believes its brand strength, app traffic, and acquisition roll-up strategy can support longer-term margin recovery.
The main risks discussed were Roto-Rooter’s ongoing dependence on paid digital leads, rising marketing costs, and higher fuel expenses, all of which pressure margins in the near term. Management also acknowledged that newly acquired franchise territories start with much lower EBITDA margins, so the acquisition strategy can mute segment margins before integration benefits show up.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.1%
- Shares Outstanding
- 13.01M
- Float Shares
- 12.77M
of shares held by institutions
537 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CHE, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Buy | Jun 24, 25 | Filing → |
| Byron DonaldsHouse · FL19 | Sell | Mar 6, 25 | Filing → |
| Byron DonaldsHouse · FL19 | Sell | Mar 6, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Feb 13, 24 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Jan 31, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 11, 23 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Sell | Sep 29, 21 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | Mar 29, 21 | Filing → |
| Greg GianforteHouse · MT00 | Sell | Oct 13, 20 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Jun 24, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.48M | ▲ 147.59K |
| Vanguard Group Inc | 1.47M | ▼ 66.23K |
| Aqr Capital Management LLC | 972.47K | ▲ 556.86K |
| Vanguard Portfolio Management LLC | 787.07K | ▼ 28.63K |
| Vanguard Capital Management LLC | 604.42K | ▼ 31.65K |
| Acadian Asset Management LLC | 461.75K | ▲ 8.51K |
| State Street Corp | 439.11K | ▼ 5.61K |
| Geode Capital Management, LLC | 402.06K | ▼ 11.89K |
| Jpmorgan Chase & Co | 386.29K | ▼ 17.11K |
| Boston Partners | 377.00K | ▲ 96.31K |
| Advisors Asset Management, Inc. | 335.47K | ▲ 334.47K |
| Dimensional Fund Advisors LP | 271.26K | ▲ 10.70K |
Held by 535 ETFs
Biggest fund positions in CHE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | LEE SPENCER S | other | 60 |
| Nov 11, 26 | LEE SPENCER S | sell | 1,000 |
| Nov 3, 26 | MCNAMARA KEVIN J | sell | 2,000 |
| Nov 2, 26 | LEE SPENCER S | sell | 920 |
| Oct 20, 26 | Wherley Joel L | other | 12,686 |
| Oct 20, 26 | LEE SPENCER S | other | 7,125 |
| Oct 20, 26 | Judkins Brian C | other | 9,392 |
| Oct 20, 26 | HUTTON THOMAS C | other | 3,964 |
| Oct 20, 26 | Witzeman Michael D | other | 12,686 |
| Oct 20, 26 | MCNAMARA KEVIN J | other | 36,693 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CHE coverage
Recent articles, reports, and earnings notes.
No research on CHE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CHE report →Danske Bank A S Buys New Shares in Chemed Corporation $CHE
defenseworld.net · Nov 19
Buy 5 Stocks at 52-Week High With More Upside for the Short Term
zacks.com · Nov 18
Chemed: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 17
2,372 Chemed Corporation $CHE Shares Sold by Fifth Third Bancorp
defenseworld.net · Nov 17
Chemtrade Logistics Income Fund (CHE.UN:CA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 16
Here's Why Chemed (CHE) is a Strong Momentum Stock
zacks.com · Nov 10
Chemed Corporation (CHE) Presents at 2026 UBS Global Healthcare Conference Transcript
seekingalpha.com · Nov 9
Chemed Corporation Declares Quarterly Dividend of 70 Cents
globenewswire.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.